Today: 29 March 2026
Subscribe
Browse Category

Artificial Intelligence 20 October 2025 - 21 October 2025

OpenAI Unveils ChatGPT Atlas Browser — Google Shares Tumble in AI Search Showdown

OpenAI Unveils ChatGPT Atlas Browser — Google Shares Tumble in AI Search Showdown

OpenAI launched ChatGPT Atlas, an AI-powered web browser, on Oct. 21, 2025, with global availability on macOS and other platforms coming soon. Atlas features deep ChatGPT integration, split-screen browsing, and an “Agent” mode for automated tasks. Alphabet shares fell 3–4% on the news. Analysts maintain bullish targets for Google, Microsoft, and Nvidia amid rising AI competition.
21 October 2025
·
Salesforce Stock Soars After Dreamforce AI Bombshell – What Investors Need to Know (Oct. 21, 2025)

Salesforce Stock Soars After Dreamforce AI Bombshell – What Investors Need to Know (Oct. 21, 2025)

Salesforce shares rose about 4–7% in mid-October after CEO Marc Benioff set a new FY2030 revenue target above $60 billion and detailed new AI integrations at Dreamforce. CRM opened at $254 on Oct. 21 and traded into the $260s, rebounding from multi-month lows. Q2 FY2026 results beat forecasts, but Q3 guidance was soft. Analysts remain cautiously optimistic, with an average 12-month target near $330.
21 October 2025
··········
OpenAI’s DevDay Bombshells: No-Code AgentKit, ChatGPT App Store & Jony Ive’s AI Vision

OpenAI’s AI Browser Bombshell Sends Google Shares Tumbling – AI Browser Wars Ignite

OpenAI will hold a livestream at 1 PM ET on Oct. 21, 2025, teasing a major product widely believed to be an AI-powered web browser. A brief teaser clip showed browser tabs, and CEO Sam Altman called it “a new product I’m quite excited about.” Alphabet shares fell 4% on the news, as investors worried about competition for Google’s core business. Reports say the browser will integrate ChatGPT and automate web tasks.
21 October 2025
······
Intel Stock Explodes: 10% U.S. Stake, Nvidia Deal & AI Hype Fuel Surge

Intel Stock Rally Pushes Limits: 10% U.S. Stake, AI Hype Fuel Surge – Will It Last?

Intel stock traded near $37.80 on Oct. 21, 2025, after hitting a 52-week high of $39.65 amid an 85% year-to-date surge. Major investments from the U.S. government, Nvidia, and SoftBank fueled gains, but Intel posted a $18.8 billion loss in 2024 and remains unprofitable. Wall Street remains cautious, with price targets below current levels. Intel’s $175 billion market cap trails AMD and Nvidia despite the rally.
21 October 2025
···
Bitcoin Boom & $500M AI Data Deal Send Bitfarms (BITF) Stock Soaring — 148% YTD Gains

Bitcoin Boom and AI Pivot Send Bitfarms (BITF) Stock Soaring – Will the Rally Last?

Bitfarms shares closed at $5.01 last week, up nearly 19% and about 148% year-to-date, after hitting a 52-week high of $6.20 on Oct. 14. The company named Jonathan Mir as CFO, replacing Jeff Lucas, and upsized a convertible note offering to $500 million. Bitfarms’ stock remains volatile, closely tracking Bitcoin, which topped $125,000 in early October. Analysts are positive but note Bitfarms is still unprofitable.
21 October 2025
···
Oracle Stock’s Wild AI Ride: Soaring 70% YTD Then a Sudden Plunge – What’s Next for ORCL?

Oracle Stock’s Wild AI Ride: Soaring 70% YTD Then a Sudden Plunge – What’s Next for ORCL?

Oracle shares trade in the high $270s on Oct. 21, 2025, after plunging from over $300 last week. The stock dropped 6.9% on Oct. 17 and another 4.9% on Oct. 20 following profit-taking and doubts over Oracle’s AI targets. Despite the pullback, ORCL remains up about 70–75% year-to-date, fueled by major AI deals and a raised 2030 revenue goal. Market cap stands near $790 billion.
21 October 2025
··
NVIDIA Stock Set to Soar? Latest AI Boom & Stock Forecast Revealed

AI Gold Rush Sends Nvidia Soaring: NVDA Stock Near Highs as $100B OpenAI Deal, China Ban & New Chips Define 2025

Nvidia shares traded near $182 on Oct. 21, 2025, close to their record high of $195 set earlier this month. The company reported Q2 revenue of $46.7 billion, up 56% year-over-year, despite losing all China AI chip sales due to U.S. export bans. Nvidia announced major AI partnerships, including a $100 billion deal with OpenAI and a $5 billion stake in Intel. Wall Street remains bullish, with most analysts rating NVDA a “Buy.”
21 October 2025
··
Salesforce (CRM) Stock Soars on $60B AI Bet – Can the Cloud Giant’s Rally Last?

Salesforce Stock Surges After $60B AI Bombshell – Here’s What’s Next (Oct 20, 2025)

Salesforce shares surged nearly 7% to $253 on Thursday, Oct. 16, 2025, after unveiling new long-term revenue targets and AI plans at Dreamforce. The stock eased to close Friday near $243 and traded in the mid-$240s Monday. Year-to-date, CRM is down about 27–28%. Wall Street analysts remain mostly bullish, with average price targets around $330.
20 October 2025
····
Alibaba’s 2025 Tech Rally: AI Gold Rush, Stock Soars & What’s Next for 9988.HK

Alibaba Stock Near 4-Year High as AI Ambitions Ignite Rally – Will BABA’s Surge Last?

Alibaba shares traded near $166 on October 20, 2025, close to their highest since 2019 and up about 85–97% year-to-date. Cloud revenue rose 26% last quarter, and management pledged a ¥380 billion tech investment. The stock briefly hit the mid-$170s before pulling back on U.S.–China tensions. Analysts remain bullish, with most price targets in the high-$180s to $240.
20 October 2025
···
🚀 CleanSpark (CLSK) Stock Surges on $120K Bitcoin Rally and $200M Crypto Credit Boost

CleanSpark (CLSK) Stock Skyrockets on Bitcoin Rally and Bold AI Pivot – What’s Next?

CleanSpark shares surged up to 13% intraday on Oct. 20 after announcing a pivot into AI data centers and appointing AI veteran Jeffrey Thomas to lead the division. The stock has more than doubled in 2025, trading near $23 after record Bitcoin prices and expansion news. CleanSpark secured $400 million in bitcoin-backed credit, keeping its 13,000+ BTC holdings intact. Most analysts rate the stock a Buy, with targets up to $26.
20 October 2025
··
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Recursion Pharmaceuticals shares jumped over 16% to $6.80 intraday on Oct. 20, capping a volatile month that saw a 44% gain and heavy trading volume. CEO Chris Gibson sold 100,000 shares on Oct. 10 for about $604,000, drawing analyst scrutiny. The company reported a Q2 net loss of $171.9 million on $19.2 million revenue. Recursion recently acquired Exscientia in a $630 million all-stock deal.
20 October 2025
··
Adobe’s AI Foundry Unveiled: Custom Brand AI Models and What Investors Are Saying

Adobe’s AI Foundry Unveiled: Custom Brand AI Models and What Investors Are Saying

Adobe launched AI Foundry on Oct. 20, 2025, offering enterprises custom generative AI models built on Firefly and trained on proprietary data. Disney Imagineering and Home Depot are early clients. Adobe shares traded flat at $333, with analysts split on GenAI monetization prospects. The company also introduced Acrobat Studio, adding AI-powered “knowledge hubs” to PDFs.
20 October 2025
·
Palantir Stock Skyrockets on Massive UK AI-Defense Pact – Could PLTR Eclipse Oracle by 2030?

Palantir Stock Skyrockets on Massive UK AI-Defense Pact – Could PLTR Eclipse Oracle by 2030?

Palantir shares closed near $180 on Oct. 20, 2025, up about 300% this year, with market cap around $400 billion. The company secured a UK government deal in September worth up to £1.5 billion, including a new London HQ and its largest-ever UK defense contract. Q2 revenue rose 48% year-over-year to $1.03 billion. Palantir reports Q3 results Nov. 3.
20 October 2025
···
Supermicro (SMCI) Stock Soars: Hedge Funds Snatch Up Shares as AI Data Center Boom Accelerates

Supermicro (SMCI) Stock Soars: Hedge Funds Snatch Up Shares as AI Data Center Boom Accelerates

CEO Charles Liang sold 200,000 SMCI shares (~$12M) in late July, while other executives disposed of nearly 290,000 more, bringing insider sales to about 490,000 shares (~$28M) last quarter. SMCI missed Q2 earnings estimates and cut its full-year revenue target to at least $33B. Shares surged from ~$48 in late September to $52.18 on Oct. 20. Wall Street consensus remains “Hold,” with average price targets in the mid-$40s.
20 October 2025
····
GSI’s AI Breakthrough Slashes Energy by 98% – GPU-Killer Chip Sparks 200% Stock Rally

GSI’s AI Breakthrough Slashes Energy by 98% – GPU-Killer Chip Sparks 200% Stock Rally

GSI’s Gemini-I APU matched NVIDIA A6000 GPU throughput on large-scale AI tasks while using over 98% less energy, according to a Cornell-led study. The chip accelerated retrieval tasks up to five times faster than standard CPUs. NASDAQ:GSIT shares surged about 200% on Oct. 20, 2025, after the announcement. Analysts warn GSI’s revenues remain low and losses deep despite the breakthrough.
20 October 2025
···
Intel Stock Surges 80% on AI Chip Hype – Can $INTC Keep Flying?

Intel (INTC) Stock Soars to Multi-Year High on AI Hype, Big Backers – What’s Next?

Intel shares traded near $37 on Oct. 20, 2025, close to a two-year high after surging 85% year-to-date. The rally follows a $10 billion U.S. government stake and Nvidia’s $5 billion investment. Despite AI-driven optimism and major partnership rumors, Intel remains unprofitable, posting an $18.8 billion loss in 2024. Analysts are divided, with most price targets below current levels.
20 October 2025
···
Bitfarms Stock Skyrockets 148% YTD on Bitcoin Boom and AI Pivot – Latest News & Outlook

Bitfarms Stock Skyrockets on Bitcoin Boom: $500M Deal, AI Pivot Fuel 148% Rally

Bitfarms Ltd. (NASDAQ: BITF) closed at $5.01 on Oct. 17, 2025, up 19% for the week and 148% year-to-date, after hitting a 52-week high of $6.20. The company replaced its CFO, announced a $500 million convertible note deal, and expanded into AI and HPC data centers. Bitcoin’s surge above $125,000 has boosted mining profits. Analyst targets remain mixed, with some cautioning on fundamentals.
20 October 2025
··
1 … 131 132 133 134 135 … 163

Stock Market Today

  • Kestra Medical Technologies (KMTS) Stock Under Pressure Amid Valuation Concerns
    March 28, 2026, 9:45 PM EDT. Kestra Medical Technologies (KMTS) shares have fallen about 23% in the past month and 28% over three months to close at $19.46. Despite a 1-year shareholder return decline of roughly 17%, analysts see potential upside with a fair value estimate of $29.14, implying 33.2% undervaluation. The company aims to leverage its scalable lease-based wearable defibrillator fleet for revenue growth and margin expansion. However, its price-to-sales ratio of 13.6x far exceeds the industry average of 2.8x, suggesting notable valuation risk if growth or margins falter. Investors should weigh prospects of rapid revenue expansion against risks tied to device adoption and capital intensity in Kestra's business model.
Go toTop